Document is current
Any future updates will be listed below
-
Authors
Ishiko, Shinya
Tanaka, Akihito
Takeda, Asami
Hara, Masayuki
Hamano, Naoto
Koizumi, Masahiro
Ueno, Toshinori
Hayashi, Hiroki
Kondo, Atsushi
Nagai, Sadayuki
Aoto, Yuya
Sakakibara, Nana
Nagano, China
Horinouchi, Tomoko
Yamamura, Tomohiko
Ninchoji, Takeshi
Shima, Yuko
Nakanishi, Koichi
Yoshikawa, Norishige
Iijima, Kazumoto
Nozu, Kandai
- License Information
-
More Information
Article History
Received: 10 December 2020
Accepted: 11 March 2021
First Online: 20 March 2021
Declarations
:
: Kazumoto Iijima reports grants from Daiichi Sankyo, Co., Ltd., personal fees from Kyowa Kirin Co., Ltd., and Integrated Development Associates, and has a patent on antisense nucleotides for exon skipping therapy in Alport syndrome issued. Kandai Nozu has received consulting fees from Kyowa Kirin Co., Ltd.; lecture fees from Kyowa Kirin Co., Ltd., Novartis Pharmaceuticals Corporation, and Chugai Pharmaceutical Co., Ltd.; and has filed a patent application on the development of antisense nucleotides for exon skipping therapy in Alport syndrome.
: All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the Institutional Review Board of Kobe University Graduate School of Medicine (IRB approval number B190137) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Comprehensive informed consent was obtained from all individual participants in the study and/or their guardians regarding the use of the patients’ clinical data.
: Informed consent was obtained from all individual participants included in the study.
